Earlier MI Diagnosis with Sensitive Cardiac Troponin

Katherine Soreng, PhD, Director, Clinical and Scientific Liaisons, Siemens Healthcare Diagnostics |  2015-04-22

The World Health Organization reports that cardiovascular disease is the number one cause of death in the industrialized world. Of the deaths attributed to CVD, an estimated 7.3 million were due to coronary heart disease, with another 6.2 million deaths caused by stroke. In an emergency situation, cardiologists and urgent care physicians face the same challenge in triaging patients who present with chest pain: (1) is this patient experiencing a cardiac event? (2) if not, how soon can I confidently rule him/her out? and (3) if so, how soon can I get him/her the care he/she needs?

Cardiac troponin, the preferred biomarker in myocardial infarction (MI) testing due to its specificity of myocardial damage (elevated in all AMIs), is one of the tools clinicians have at their disposal to aid in the earlier diagnosis of MI


Learning objectives:

  • Review the current troponin testing guidelines
  • Learn about the comparability of guideline approved sensitive and high sensitive assays in the earlier diagnosis of MI
  • Understand how to use serial measurements, especially patients with non-ST-elevation acute myocardial infarction


Register: www.meetme.net/troponin

Webinars are complimentary and remain available online for 12 months after the live webinar date. Log on and learn!

For additional information on troponin, visit www.siemens.com/troponin.